drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically modified CAR T-cell therapy targeting CLEC12A (CD371/CLL-1) on AML cells; incorporates CD3ζ-based CAR signaling with costimulation and is "armored" to secrete IL-18 to enhance expansion/persistence, Th1 polarization, and recruitment/activation of innate immune cells, thereby broadening anti-leukemia activity. Administered after lymphodepleting chemotherapy in relapsed/refractory AML.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a CAR that binds CLEC12A (CD371/CLL-1) on AML cells. CAR signaling via CD3zeta with costimulation triggers T-cell cytotoxicity against leukemic blasts and stem cells. The construct is armored to secrete IL-18, which enhances CAR T expansion and persistence, promotes Th1 polarization and IFN-gamma–driven immunity, and recruits/activates innate immune cells (e.g., NK cells, macrophages), broadening anti-leukemia activity after lymphodepletion.
drug_name
CD371-YSNVZ-IL-18 CAR T cells (ArmoRed)
nct_id_drug_ref
NCT06017258